Related by context. All words. (Click for frequent words.) 72 leukemia CLL 72 CHOP chemotherapy 71 indolent NHL 71 heavily pretreated 70 previously untreated follicular 70 imatinib Gleevec ® 70 DLBCL 70 leukemia AML 70 heavily pretreated patients 69 metastatic renal cell carcinoma 69 bendamustine 69 chronic lymphocytic leukemia CLL 69 imatinib resistant 69 mRCC 69 metastatic malignant 69 relapsed refractory aggressive 68 anti leukemic 68 CLL SLL 68 cell lymphoma CTCL 68 dasatinib Sprycel ® 68 relapsed refractory multiple myeloma 67 Fludarabine 67 rituximab refractory 67 follicular NHL 67 chronic myelogenous leukemia CML 67 gemcitabine Gemzar ® 66 leukemia CML 66 carboplatin paclitaxel 66 relapsed MM 66 chronic myeloid leukemia CML 66 multiple myeloma MM 66 Diffuse Large B 66 HER2 positive metastatic breast 66 dasatinib Sprycel 66 Amrubicin 66 vinorelbine 66 leukemia ALL 66 superficial bladder cancer 66 resistant ovarian cancer 65 gemcitabine Gemzar 65 CVP chemotherapy 65 relapsed ovarian cancer 65 refractory acute myeloid 65 rituximab 65 fludarabine 65 receptor tyrosine kinase inhibitor 65 refractory chronic myeloid 65 etoposide 65 B CLL 65 erlotinib Tarceva ® 65 imatinib therapy 65 Marqibo 65 myelodysplastic syndrome MDS 65 imatinib Gleevec 65 pertuzumab 65 stage IIIB 65 biologic therapy 65 diagnosed Ph + 65 milatuzumab 65 Rituxan rituximab 65 axitinib 65 hematologic malignancies 65 liposomal doxorubicin 65 temozolomide TMZ 65 MabCampath 65 Rituximab 65 refractory CTCL 64 sunitinib malate 64 IMGN# 64 recurrent glioblastoma multiforme 64 recurrent glioblastoma 64 PEG IFN 64 relapsed multiple myeloma 64 relapsing multiple sclerosis 64 antitumor activity 64 decitabine 64 CVP cyclophosphamide vincristine 64 pomalidomide 64 Epratuzumab 64 refractory cutaneous T 64 xenograft models 64 Gleevec resistant 64 sunitinib Sutent ® 64 Relapsed Refractory 64 remission induction 64 small lymphocytic lymphoma 64 gemcitabine carboplatin 64 refractory indolent non 64 Hodgkin lymphoma NHL 64 hA# 64 galiximab 64 cytotoxic chemotherapy 64 trabectedin 64 non metastatic osteosarcoma 64 pegylated liposomal doxorubicin 64 acute GvHD 64 mapatumumab 64 platinum refractory 64 elacytarabine 64 refractory chronic lymphocytic 63 HDACi 63 refractory metastatic colorectal cancer 63 demonstrated antitumor activity 63 cutaneous T cell 63 Pemetrexed 63 temozolomide 63 adriamycin 63 HBeAg positive 63 metastatic RCC 63 Ofatumumab 63 liposomal formulation 63 azacitidine 63 paclitaxel carboplatin 63 huN# DM1 63 sorafenib Nexavar ® 63 non Hodgkin lymphomas 63 refractory AML 63 systemic anaplastic large 63 lymphoid malignancies 63 oblimersen 63 cell malignancies 63 Blinatumomab 63 Xanafide 63 Hodgkin lymphoma HL 63 lupus nephritis 63 ixabepilone 63 Pharmacokinetics PK 63 blinatumomab 63 chlorambucil 63 refractory multiple myeloma 63 metastatic malignant melanoma 63 metastatic hormone refractory 63 refractory NSCLC 63 trastuzumab Herceptin ® 63 TEMODAL 63 Doxil ® 63 docetaxel chemotherapy 63 cutaneous T 63 complete remissions 63 Telintra 63 lymphoma CTCL 63 follicular lymphoma 63 refractory 63 relapsed 63 tyrosine kinase inhibitor 63 cetuximab Erbitux R 63 estramustine 63 obatoclax 63 mTOR inhibitor 63 melphalan prednisone 63 temsirolimus 63 refractory CLL 63 veltuzumab 63 BCG refractory 63 cell acute lymphoblastic 63 tanespimycin 63 amrubicin 63 chemotherapy regimens 63 Toxicities 63 gastrointestinal stromal tumor GIST 63 SCCHN 63 CHOP cyclophosphamide doxorubicin vincristine 62 chemotherapy docetaxel 62 dacarbazine 62 gastrointestinal stromal tumors GIST 62 Lenalidomide 62 alkylating agent 62 unresectable 62 histologies 62 romidepsin 62 bortezomib Velcade R 62 HRPC 62 ara C 62 recurrent GBM 62 pancreatic adenocarcinoma 62 prednisolone chemotherapy 62 myelofibrosis 62 Myelofibrosis 62 vidofludimus 62 sorafenib Nexavar 62 recurrent NSCLC 62 cell chronic lymphocytic 62 Relapsed 62 dasatinib 62 AQ4N 62 ribavirin RBV 62 thalidomide Thalomid 62 CYT# potent vascular disrupting 62 mCRC patients 62 ritonavir boosted 62 Myelodysplastic Syndrome MDS 62 pediatric Crohn disease 62 biliary tract cancer 62 systemic ALCL 62 ovarian carcinoma 62 sunitinib 62 antibody MAb 62 monotherapy 62 YONDELIS 62 lumiliximab 62 chemoradiotherapy 62 imatinib mesylate 62 dose escalation clinical 62 paclitaxel Taxol 62 ZACTIMA 62 pediatric acute lymphoblastic 62 low dose cytarabine 62 VELCADE melphalan 62 refractory ovarian cancer 62 VNP#M 62 vandetanib 62 Aplidin 62 Traficet EN 62 Ph + acute lymphoblastic 62 abiraterone acetate 62 cyclophosphamide doxorubicin vincristine 62 Carfilzomib 62 MDS AML 62 acute myelogenous leukemia AML 62 hypereosinophilic syndrome 62 cilengitide 62 nab paclitaxel 62 Flu Cy 62 cabazitaxel 62 enzastaurin 62 Pixantrone 62 NSCLC 62 papillary renal cell carcinoma 62 follicular non 62 follicular Non Hodgkin 62 relapsed mantle 62 lintuzumab 62 Annamycin 62 mitomycin 62 tumor xenograft models 62 Nilotinib 62 diagnosed multiple myeloma 62 alvespimycin 62 cancer mCRC 62 relapsed leukemia 62 alfa 2a 62 evaluable patients 62 Cutaneous T 61 relapsing remitting multiple sclerosis 61 ofatumumab 61 RoACTEMRA 61 bevacizumab Avastin ® 61 taxane chemotherapy 61 #mg/m# [001] 61 docetaxel Taxotere R 61 pegylated interferon alfa 2a 61 Cloretazine 61 alefacept 61 relapsed CLL 61 TREANDA 61 IMC A# 61 cell lymphoma ALCL 61 ZEVALIN 61 HSP# inhibitor 61 mycophenolate mofetil MMF 61 Cloretazine ® 61 cetuximab Erbitux ® 61 phase Ib 61 CTCL 61 Erlotinib 61 metastatic GIST 61 Bortezomib 61 ASCT 61 evaluating tivozanib 61 anti angiogenic agents 61 Irinotecan 61 Kit CD# positive 61 CR CRu 61 HGS# 61 acute leukemias 61 Non Hodgkin 61 HuMax CD4 61 nilotinib 61 idarubicin 61 humanized monoclonal antibody 61 boosted protease inhibitor 61 CLL 61 lenalidomide Revlimid R 61 GvHD 61 T#I [002] 61 EOquin 61 micafungin 61 Bezielle 61 cytarabine 61 Soft Tissue Sarcoma 61 docetaxel Taxotere 61 ganetespib 61 bortezomib 61 LHRH receptor positive 61 Ph + 61 metastatic pancreatic 61 gastrointestinal stromal tumors 61 Omacetaxine 61 Vicinium TM 61 ibritumomab tiuxetan 61 castrate resistant prostate cancer 61 imatinib 61 advanced metastatic renal 61 myelofibrosis MF 61 pegfilgrastim 61 PXD# 61 depsipeptide 61 TACE 61 Onrigin 61 eosinophilic asthma 61 novel histone deacetylase 61 Fludara 61 Phase Ib clinical 61 Gleevec imatinib mesylate 61 prostate cancer HRPC 61 hematological cancers 61 metastatic colorectal cancer 61 hypomethylating agents 61 conventional DMARDs 61 cytarabine daunorubicin 61 plus dexamethasone 61 Pazopanib 61 Personalized Immunotherapy 61 resectable 61 Phase III randomized controlled 61 relapsed acute myelogenous 61 Voreloxin 61 dexamethasone Decadron 61 histone deacetylase HDAC inhibitor 61 HBeAg negative 61 chronic myeloid 61 tumors GIST 61 panobinostat 61 solid tumors 61 FOLFIRI 61 AVASTIN 61 Taxotere ® 61 FOLFOX6 61 Decitabine 61 standard chemotherapy regimen 61 neratinib 61 acute myeloid 61 GW# [003] 61 Trastuzumab 61 azacytidine 60 docetaxel Taxotere ® 60 Bosutinib 60 Imprime PGG 60 relapsed SCLC 60 recurrent malignant glioma 60 HBeAg positive patients 60 rALLy clinical trial 60 lenalidomide dexamethasone 60 haematological malignancies 60 nucleoside analog 60 CML CP 60 KRAS mutations occur 60 cytogenetic responses 60 follicular lymphoma FL 60 autoantibody positive 60 protease inhibitor PI 60 generation purine nucleoside 60 Ceflatonin 60 Follicular Lymphoma 60 dose dexamethasone 60 gefitinib Iressa 60 eribulin mesylate 60 Ph + ALL 60 chronic eosinophilic leukemia 60 ribavirin therapy 60 ErbB2 positive 60 androgen independent 60 locoregional 60 EOquin TM 60 plus DOXIL 60 Peginterferon 60 TroVax ® 60 Aflibercept 60 Tarceva TM 60 polycythemia vera essential thrombocythemia 60 neoadjuvant chemotherapy 60 Neuvenge 60 baminercept 60 neoadjuvant 60 cell lymphomas 60 fludarabine cyclophosphamide 60 pan HDAC inhibitor 60 nilotinib Tasigna 60 fluoropyrimidine 60 neurologic progression 60 metastatic CRC 60 recurrent ovarian cancer 60 KRN# 60 untreated multiple myeloma 60 immunomodulator 60 evaluating REVLIMID 60 Acute Myeloid Leukemia AML 60 potent antiproliferative 60 Vidaza azacitidine 60 Perifosine 60 5FU 60 phase IIb clinical 60 EGFR mutation positive 60 bortezomib Velcade 60 crizotinib PF # 60 REVLIMID 60 polymerase inhibitor 60 targeted antifolate 60 Velcade bortezomib 60 Degarelix 60 registrational 60 myeloproliferative diseases 60 LymphoStat B belimumab 60 Cytoxan 60 registrational trial 60 mitoxantrone 60 daunorubicin 60 essential thrombocythemia ET 60 mu opioid receptor antagonist 60 castration resistant prostate cancer 60 Platinol 60 Sipuleucel T 60 neoadjuvant treatment 60 angiogenesis inhibitor 60 irinotecan containing 60 IIa trial 60 refractory myeloma 60 trastuzumab Herceptin R 60 metastatic uveal melanoma 60 alkylating agents 60 Apoptone 60 MGd 60 dose cohorts 60 vinca alkaloid 60 indolent lymphoma 60 ofatumumab HuMax CD# 60 ISTODAX ® 60 targeting CD# 60 SPRYCEL ® 60 cisplatin gemcitabine 60 gemcitabine cisplatin 60 myelodysplastic myeloproliferative diseases 60 Treanda 60 IAP inhibitor 60 blinded randomized placebo controlled 60 5-FU/LV 60 mouse xenograft models 60 relapsed Acute Myeloid 60 refractory Hodgkin lymphoma 60 Alocrest 60 doxorubicin cyclophosphamide 60 Panzem R NCD 60 interferon alfa 2a 60 Fludara ® 60 DOXIL 60 rituximab refractory follicular 60 posaconazole 60 Phase Ib 60 NMIBC 60 Clofarabine 60 severe oral mucositis 60 fistulizing Crohn disease 60 cytogenetic response 60 HER2 + 60 Allovectin 7 ® 60 Campath alemtuzumab 60 PEGylated interferon beta 1a 59 MAGE A3 ASCI 59 olmesartan 59 Revlimid lenalidomide 59 HGS ETR1 59 autologous stem cell 59 everolimus tablets 59 Cloretazine R VNP#M 59 EGFR expressing 59 ulcerative colitis UC 59 basal cell carcinoma BCC 59 Tarceva erlotinib 59 advanced NSCLC 59 Dasatinib 59 SUTENT 59 methotrexate MTX 59 sorafenib 59 FTY# fingolimod 59 Follicular lymphoma 59 Mantle Cell Lymphoma 59 mycophenolate mofetil 59 Dacogen injection 59 Neoadjuvant 59 prostate cancer mCRPC 59 CRp 59 TO AVOID PREGNANCY WHILE 59 Zarnestra 59 castrate resistant 59 Talabostat 59 caspofungin 59 somatostatin analog 59 immunomodulatory therapy 59 IV metastatic melanoma 59 BAY #-# 59 refractory colorectal cancer 59 chemoradiation 59 cyclophosphamide Cytoxan 59 Phase 1b trial 59 MabThera Rituxan 59 evaluable 59 CIMZIA TM 59 AP# [003] 59 temsirolimus Torisel ® 59 farletuzumab 59 hormone refractory prostate cancer 59 fallopian tube carcinoma 59 chemoresistant 59 tocilizumab 59 mitoxantrone plus 59 lymphocytosis 59 visilizumab 59 FOLFOX chemotherapy 59 differentiated thyroid 59 standard chemotherapy regimens 59 Temozolomide 59 tigecycline 59 non Hodgkin Lymphoma 59 OncoVEX GM CSF 59 anti EGFR antibody 59 Pegasys ® 59 ceftazidime 59 refractory metastatic 59 JAK inhibitor 59 palifosfamide 59 potentially hepatotoxic 59 rituximab Rituxan 59 Ibritumomab Tiuxetan 59 Cloretazine R 59 relapsed AML 59 platelet inhibitor 59 plus prednisone prednisolone 59 soft tissue sarcomas 59 chimeric monoclonal antibody 59 subcutaneously administered 59 cetuximab 59 paclitaxel poliglumex 59 myelodysplastic syndromes 59 EFAPROXYN 59 Akt inhibitor 59 chemotherapeutic drug 59 docetaxel 59 AKT inhibitor 59 Castration Resistant Prostate Cancer 59 OHR/AVR# 59 luteinizing hormone releasing 59 sodium glucose cotransporter 59 erlotinib Tarceva 59 BRAF inhibitor 59 investigational monoclonal antibody 59 selective modulator 59 refractory CML 59 Laquinimod 59 velafermin 59 renal cell carcinoma 59 Chronic Lymphocytic Leukemia CLL 59 Torisel 59 proteasome inhibitor 59 ALK inhibitor 59 leukemia APL 59 comparator arm 59 glatiramer acetate GA 59 cisplatin chemotherapy 59 Herceptin trastuzumab 59 rALLy 59 subcutaneous formulation 59 Taxotere R 59 ACTEMRA TM 59 Benlysta belimumab 59 colon carcinoma 59 ascending doses 59 Denufosol 59 prostate carcinoma 59 T#I mutation 59 elotuzumab 59 Vandetanib 59 tumor lysis syndrome 59 APTIVUS r 59 Quinamed 59 squamous cell carcinoma SCC 59 paclitaxel Taxol R 59 taxane therapy 59 panitumumab Vectibix 59 INCB# [002] 59 KRAS wild 59 viral kinetics 59 pheochromocytoma 59 Vidofludimus 59 EGFR inhibitors 59 cell lymphoma DLBCL 59 Azacitidine 59 Peginterferon alfa 2b 59 Navelbine ® 59 stage IIIb IV 59 Chronic lymphocytic leukemia CLL 59 macroglobulinemia 59 low dose dexamethasone 59 FOLPI 59 HGS ETR2 59 PD LID 59 AEG# 59 K ras mutations 59 selectively binds 59 AEGR 59 anthracycline taxane 59 PKC# 59 SCH # 59 DMARD 59 situ CIS 59 TMC# C# 59 octreotide 59 achieve sustained virologic 59 oral prodrug 59 carfilzomib 59 unresectable stage 59 cisplatin vinorelbine 59 assessing T DM1 59 bone metastases 59 belinostat 59 TORISEL 59 Chronic Myeloid Leukemia 59 corticosteroid dexamethasone 59 Pegylated Interferon 59 Arranon 59 PREZISTA r 59 Virulizin ® 59 IV malignant melanoma 59 liposomal amphotericin B 59 CD# antibody [001] 59 Paraplatin ® 59 EGFR HER2 59 Pathway Inhibitor 59 orally administered inhibitor 59 antigen CD# 59 cyclophosphamide methotrexate 59 hematologic 59 ZOLINZA 59 Alemtuzumab 59 Plicera 59 Acute Myeloid Leukaemia AML 59 Proxinium TM 59 PEGylated Fab fragment 59 estrogen receptor progesterone receptor 59 intravesical therapy 59 erythropoietic 59 epratuzumab 59 microwave hyperthermia 59 T#I mutant 59 dose escalation Phase 59 Chronic Myelogenous Leukemia CML 59 Non Hodgkin Lymphomas 59 phase IIb trial 59 Phase IIIb clinical 59 relapsed follicular 59 adalimumab Humira 58 imetelstat 58 receptor inhibitor 58 pegylated interferon alfa 58 small molecule tyrosine 58 refractory follicular 58 cytotoxic 58 overlapping toxicities 58 dextromethorphan quinidine 58 IFN α 58 glufosfamide 58 rheumatoid arthritis psoriatic arthritis 58 EpCAM 58 non resectable 58 pegylated 58 metastatic renal cell 58 CYC# 58 CLL8 58 Sutent sunitinib 58 iniparib 58 PNP inhibitor 58 MyVax R 58 ON #.Na 58 nilotinib Tasigna ® 58 Imatinib mesylate 58 metastatic colorectal carcinoma 58 metastatic gastric 58 cyclophosphamide 58 radiotherapy RT 58 desvenlafaxine succinate 58 MCyR 58 neurological manifestations 58 myeloid 58 gemtuzumab ozogamicin 58 topotecan 58 Copegus ribavirin 58 fluorouracil 58 Relapsed Refractory Aggressive 58 Vitaxin 58 HBeAg negative patients 58 antitumour activity 58 chronic HBV 58 orally bioavailable 58 Neulasta ® 58 G CSF 58 5 FU 58 Gemcitabine 58 seliciclib 58 advanced hepatocellular carcinoma 58 deletion 5q 58 oral ridaforolimus 58 effector function 58 Targretin 58 IV NSCLC 58 histologically confirmed 58 plus prednisone 58 Camptosar ® 58 trabedersen 58 dacarbazine DTIC 58 indolent follicular non 58 aHUS 58 paclitaxel Taxol ® 58 zalutumumab 58 doxorubicin docetaxel 58 non splenectomized 58 erlotinib 58 Evoltra ® 58 VELCADE 58 pazopanib 58 6 mercaptopurine 58 malignant ascites 58 cisplatin carboplatin 58 Seliciclib 58 bleomycin 58 haematologic 58 sunitinib Sutent 58 DMARD therapy 58 PRTX 58 glioblastoma multiforme GBM 58 beta 1a 58 perifosine 58 somatostatin analogue 58 stage IIIb 58 epithelial tumors 58 gefitinib 58 INCB# [001] 58 HCV SPRINT 58 certolizumab 58 pegylated interferon alpha 58 myelodysplastic syndromes MDS 58 metastatic castration resistant 58 multiple myeloma 58 Taxotere chemotherapy 58 IGF 1R inhibitor 58 HuMax CD# 58 alpha 2a 58 relapsed refractory ALL 58 interferon alfa 2b 58 HuMax EGFr 58 ® lenalidomide 58 TAXOTERE R 58 teriflunomide 58 interferon IFN 58 Ceflatonin R 58 histological subtype 58 SAI EGF 58 metastatic sarcoma 58 Pralatrexate 58 lymphopenia 58 Tofacitinib 58 intratumoral injection 58 alpha folate receptor 58 radiation sensitizer 58 phase Ph + 58 chronic HCV 58 Dapagliflozin 58 CAELYX 58 entinostat 58 BCR ABL inhibitor 58 steroid refractory ulcerative 58 imatinib resistance 58 recurrent metastatic 58 CR nPR 58 mycosis fungoides 58 Phase 1b 58 chemotherapeutic agent 58 humanised monoclonal antibody 58 Zolinza 58 voriconazole 58 Relapsing Remitting Multiple Sclerosis 58 nucleoside analogue 58 fosbretabulin 58 doxorubicin Adriamycin 58 hepatocellular carcinoma HCC 58 diagnosed glioblastoma multiforme 58 telaprevir dosed 58 CsA 58 breast carcinomas 58 TELCYTA 58 lymphoproliferative disorders 58 Phase 1b clinical 58 5-fluorouracil/leucovorin 58 Troxatyl 58 GISTs 58 MGCD# [001] 58 sorafenib tablets 58 protein kinase inhibitor 58 complete cytogenetic 58 antiangiogenic therapy 58 calcineurin inhibitor 58 carboplatin 58 Gefitinib 58 IMA# 58 mCRC 58 ZD# [001] 58 investigational compound 58 opioid induced constipation OIC 58 tyrosine kinase inhibitors 58 DMARDs 58 IRESSA 58 lymphoid blast 58 progressive PsA 58 relapsing remitting MS RRMS 58 Ph + CML 58 Clolar ® 58 PEG interferon 58 BMS # 58 EGFR expressing mCRC 58 talabostat 58 metastatic bladder 58 mg/m2 dose 58 Pivotal Study 58 Chronic Lymphocytic Leukemia 58 CANCIDAS 58 peginterferon alfa 2b 58 rheumatoid arthritis RA 58 Darusentan 58 Cimzia ® certolizumab pegol 58 SJIA 58 investigational humanized monoclonal antibody 58 Nimotuzumab 58 antimetabolite 58 gemcitabine 58 Multiple Myeloma MM 58 FEMALES SHOULD BE ADVISED 58 thymoma 58 Tasigna nilotinib 58 taxane refractory 58 Natalizumab 58 trastuzumab 58 medullary thyroid cancer 58 plus gemcitabine 58 ALB # 58 bevacizumab Avastin R 58 hepatocellular carcinomas 58 PSN# [001] 58 multi kinase inhibitor 58 Chronic lymphocytic leukemia 58 CA4P 58 bosentan 58 Azedra 58 Luteinizing Hormone Releasing Hormone 58 dose escalation 58 randomized Phase 58 hematologic toxicity 58 tumor regressions 58 Phase IIa trial 58 docetaxel cisplatin 58 acute coronary syndromes ACS 58 INC# 58 ruxolitinib 58 plus COPEGUS 58 myelofibrosis polycythemia vera 58 Phase Ib study 58 mg/m2/day 58 Phase 2a trial 58 Gleevec imatinib 58 CD# monoclonal antibody 58 riociguat 58 lymphocytic leukemia 58 PROSTVAC VF 58 Hycamtin 58 evaluating Xcytrin 58 Bevacizumab 58 mitoxantrone chemotherapy 58 Nexavar sorafenib 58 piperacillin tazobactam 58 glatiramer acetate 58 CD4 + CD# 58 acute myeloid leukemia AML 58 patients evaluable 58 FluCAM 58 HERCEPTIN 58 pain palliation 58 DEB# 58 pancreatic neuroendocrine tumors 58 INCB# [003] 58 Omacetaxine mepesuccinate 58 PCa 58 relapsing MS 58 Archexin 58 Sanofi Aventis Taxotere 58 partial remissions 58 prednisone prednisolone 58 taxane resistant 58 fluorouracil leucovorin 58 CIMZIA ™ 58 Myeloid 58 Newly Diagnosed Multiple Myeloma 58 anthracycline containing 58 noninferiority 58 ONCASPAR 58 valopicitabine 58 denileukin diftitox 58 de novo kidney transplant 58 MELAS 58 inhibitor RG# 58 PsA 58 atherothrombotic events 58 Stage IIIb 58 hematologic cancers 58 HSCT 58 ELACYT 58 TOP2A 57 pemetrexed 57 Glioblastoma Multiforme 57 doublet chemotherapy 57 CPOP R 57 Golimumab 57 randomized Phase III 57 VAPRISOL 57 DOXIL ® 57 Cell Lymphoma 57 diabetic neuropathic pain 57 tiuxetan 57 pancreatic carcinoma 57 nucleoside analogues 57 lapatinib Tykerb 57 capecitabine Xeloda 57 sorafenib Nexavar R 57 Albuferon TM 57 basiliximab 57 trans retinoic acid ATRA 57 Interferon alpha 57 randomized Phase IIb 57 immunosuppressant 57 PSN# [002] 57 lorvotuzumab mertansine 57 invasive candidiasis 57 malignant pleural mesothelioma 57 Romidepsin 57 Platinol ® 57 HuLuc# 57 Doxil 57 mTOR inhibitors 57 irinotecan doxorubicin oxaliplatin paclitaxel 57 irinotecan chemotherapy 57 NEUVENGE 57 adalimumab 57 EGFR TKI 57 goserelin 57 recurrent genital herpes 57 Cyclophosphamide 57 Yondelis ® 57 5 FU leucovorin 57 Arzerra ofatumumab 57 prostate cancer CRPC 57 Tanespimycin 57 romiplostim 57 atypical hemolytic uremic syndrome 57 Rituxan MabThera 57 lamivudine refractory patients 57 Leukemias 57 EGFr 57 rFIXFc 57 RRMS patients 57 Telcyta 57 kinase inhibitor 57 idiopathic thrombocytopenic purpura ITP 57 TKI therapy 57 Hsp# Inhibitor 57 pancreatic NET 57 proteasome inhibitor bortezomib 57 Cimzia TM 57 myeloproliferative disorders 57 TRISENOX 57 VEGF inhibitors 57 TELINTRA 57 Waldenstrom macroglobulinemia 57 RH1 57 RezularTM 57 pro apoptotic 57 multikinase inhibitor 57 Trabectedin 57 HNSCC 57 free survival PFS 57 lenalidomide Revlimid 57 Ceplene/IL-2 57 ACZ# 57 Aptivus ®